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R9 ISOLATION PROCEDURE, SPECIES IDENTIFICATION
AND CLINICAL SIGNIFICANCE OF ASPERGILLUS SPP.,
SCEDOSPORIUM SPP., AND OTHER FILAMENTOUS FUNGI IN
CYSTIC FIBROSIS
G. Manno. Microbiology Laboratory, G. Gaslini Children’s Hospital Research
Institute, University Department of Paediatrics, Genova, Italy
Aspergillus fumigatus is the most common agent associated of airways colonization
in CF, it may cause various diseases including asthma, bronchitis and aspergilloma,
as well as invasive aspergillosis after lung transplantation. The most relevant clinical
form in CF patients remains allergic broncho-pulmonary aspergillosis (ABPA).
Other ﬁlamentous fungi are increasingly reported in CF, such as Scedosporium
apiospermum and some Aspergillus spp., particularly Aspergillus ﬂavus, Aspergillus
terreus, Aspergillus niger and Aspergillus nidulans which may be found transiently.
Scedosporium apiospermum is now recognized as an important colonizer of the
airways in CF patients, but little is known about the prevalence of non-fumigatus
Aspergillus species. Some of these fungi may be responsible for allergic broncho-
pulmonary disease similar to ABPA. The microbiological diagnosis usually relies
on direct microscopic examination and culture of CF sputum samples. However,
at present, there is no standardization of mycological examination of CF samples,
the culture media used, as well as temperature or incubation times. The absence
of selective media, as an insufﬁcient incubation time, may hamper the recovery of
some species like Scedosporium apiospermum which is usually associated to the
more rapidly growing fungus Aspergillus fumigatus.
Different rate of FF occurrence are described in CF patients in Europe (France, Ger-
many, Spain, etc.) but, at the moment, very little information are available from Italy.
From 1/1/2007 to 30/09/2007, 35/220 (15.9%) of pts attending the CF Centre
of Genova where colonized by ﬁlamentous fungi. The species distribution was:
A. fumigatus (64%), A. ﬂavus (25%), S. apiospermum (9%) others (2%).
R10 A PATIENT-ORIENTED LABORATORY MODEL FOR CYSTIC
FIBROSIS (CF)
E. Fiscarelli, G. Ricciotti, P. Campagnano, A. Angioni, F. Callea. Laboratory
Department Pediatric Hospital Bambino Gesu`, Rome, Italy
The Department of Pathology and Laboratory Medicine of the Children’s Hospital
Bambino Gesu` is developing a project of “clinicization” that is leading to the tran-
sition of the traditional concept of Department into an interdepartimental network.
That implies the evolution of the academic deﬁnition of department towards a
deﬁnition of “patient-centered” department.
A series of clinico-laboratory projects are being experienced, the prototype is the
Cystic Fibrosis (CF) model.
In this model the patient represents the center of the CF universe, around which
are rotating the pertinent and competent clinical units from one side and the CF
Laboratory from the other side. Interaction and communication take place by a
directional ﬂow passing through the CF patient.
The CF Laboratory is innovative in that it carries out both clinical and laboratory
work, either diagnostic or research.
The clinical activities consist in providing a qualiﬁed reception in a comfortable
environment to patients and families by an informative and formative approach
before performing the sweat test and a genetical counseling after the results of the
various diagnostic tests.
To optimize the results the sweat test is carried out by experienced medical personnel
and nurses.
The CF Lab consists of an integrated team from four specialized Labs: Molecular
Genetics where gene mutations are searched, a speciﬁc Microbiology Lab for
cultural and sensibility tests, a section of Chemical Chemistry for analytical
determination and a dedicated histopathologist with special interest in CF.
Laboratory rounds and participation of Lab staff members into clinical grand rounds
are promoting the clinical attitude of the participants, and are expected to contribute
to the continuous improvement of the safety and quality care of CF patients.
R11 FROM RESEARCH TO CLINICAL PRACTICE. RCTs AND THEIR
EXTERNAL VALIDITY
L. Pagliaro. Professor Emeritus of Internal Medicine, University of Palermo,
Palermo, Italy
Patient care and outcomes could be improved if the knowledge from research was
better translated into practice. It has been estimated that 30−40% of patients do
not receive treatments of proven effectiveness, whereas 20−25% receive treatments
that are unnecessary or potentially harmful. This situation is in part due to two
translational blocks that thwart the passage from basic research to clinical research,
eg RCTs (type 1 translational block), and from clinical research and RCTs to clinical
practice (type 2 translational block). Frequent information gaps due to inadequate
external validity contribute substantially to the translational roadblock between
RCTs and clinical practice (type 2 translational block). The external validity of
an RCT regards the information needed to apply the trial results in the appropriate
patients and settings, but it is often neglected, inadequate and unclear. Inclusion and
exclusion criteria; ratio between randomized and eligible patients; heterogeneity,
baseline risk and comorbidity of patients; selection of participating centres and
researchers; rate and reasons of discontinuation: this is an incomplete list of the
major requirements of external validity. When the information on these (and other)
areas is inadequate or unclear, clinicians’ uncertainty and underuse or even misuse
of treatments are the consequences. The conclusions are that:
Trialists should pay to the external validity the same attention and completeness
of information they usually pay to the internal validity. Pre-established subgroup
analyses in megatrials implying patients’ heterogeneity (eg, due to comorbidity)
could be of use to guide the trial application in practice.
Clinicians should take into account the limitations of the RCTs before applying their
results, perhaps using guidelines assembling the full evidence available in order to
compensate the lack of information of the individual RCT of interest.
R12 EVIDENCE BASED MEDICINE – ONE AID IN PROVIDING GOOD
CF CARE
J. Littlewood. UK CF Trust & Hon. Paediatrician, Regional Paediatric CF Unit,
St James’s University Hospital, Leeds, United Kingdom
The survival of people with cystic ﬁbrosis has steadily improved over the years
due to increasingly effective nutritional and antibiotic treatment for the secondary
effects of the basic defect. The care the patient receives from an early age is the
main determinant of health, quality of life and length of survival; but numerous
studies show major differences between CF Centres reﬂecting different patterns of
care. The features of early management later associated with better lung function
include early diagnosis by screening, lack of symptoms and higher weight for
age at diagnosis, more clinic visits, respiratory cultures, intravenous antibiotics,
corticosteroids and mucolytics.
An information revolution has taken place over the past 10−15 years including
the growth of Evidence Based Medicine deﬁned as “the conscientious explicit and
judicious use of current best evidence in making decisions about care of individual
patients”. There are now Systematic Reviews by the Cochrane Collaboration on
more than 40 areas of treatment for CF and more in preparation. These make a
variable contribution to CF care but are often more a statistical analysis of the
methodology of the published trials rather than a practical help to the clinician –
most call for further randomized controlled trials. Although a useful record of
published work, lack of large randomized controlled trials on some areas of
treatment where beneﬁt is nevertheless quite obvious to the experienced clinician,
may delay by years the introduction of treatments later proved to be very effective
e.g. the early eradication treatment of Pseudomonas aeruginosa.
So although Evidence Based Medicine has made and continues to make a signiﬁcant
contribution to CF care, it should be regarded as but one aid to better CF care – one
additional aid to the expertise of experienced staff at CF Centres; expertise that has
been acquired over many years of treating people with CF.
R13 A NEW MODEL OF CF DISEASE: NO F508, NO KINASE?
A. Mehta, K.J. Treharne, A. Winter, R. Langley, Z. Xu1, J.H. Chen1,
D.N. Sheppard1, K. Kunzelmann2, presented by AM on behalf of authors
in 1Bristol and 2Regensburg Universities. Maternal & Child Health Sciences,
University of Dundee, Ninewells Hospital & Medical School, Dundee, United
Kingdom
Protein kinase CK2 is an essential heterodimer (a2b2) whose constitutive activity
controls inﬂammation, cancer and infection; unexplained hallmarks of CF disease.
The deletion of only one amino acid (F, phenylalanine 508) causes most cystic
ﬁbrosis (CF) and our data connects this F508-CFTR region with a malfunctioning
protein kinase binding site and suggest that DF508 induces a kinase-opathy. We
noticed immediately C terminal to F508 lies a potential CK2 consensus motif
(F508GVS511YDE; target serine, S, plus locating motif DE) and tested the idea
that F508 is needed for CK2 function towards CFTR and vice versa.
Methods: Treharne et al J Biol Chem 2007 & Am J Physiol 1994 using models of
CFTR/CK2 function (confocal, oocytes, single channel CFTR kinetics) coupled to
CK2 assay in apical membrane samples and WT (HBE) and homozygous DF508
(CFBE) cell lines.
Results: Compared to HBE membranes containing WT-CFTR, CFBE membrane
blots contain no detectable catalytic CK2a, CK2b, unaffected) without affecting
PKA/PKC. Thus membrane local CK2 is absent in CF (conﬁrmed by activity assay).
Further, unlike in wild-type nasal epithelial biopsies, those from DF508 CF patients
do not localise CK2a to the apical membrane (n>3). In oocytes co-expressing
human WT CFTR with human CK2, CFTR (but not DF508-CFTR) closes by
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~70−90% within minutes when CK2 is inhibited by its speciﬁc inhibitor (TBB, n=8,
p< 0.001) but this WT inhibition disappears when a TBB-resistant CK2 mutant is
co-expressed with WT CFTR in oocytes (n=20, p< 0.001). Single channel analysis
shows similar results in mammalian cells where TBB CK2-inhibitor closes CFTR in
cell attached (but not detached) mode consistent with a protein–protein interaction in
cell attached (but not detached) patches. The missing link to inﬂammation manifests
when NFkB elevation in Hela cells stably expressing CFTR is found to be CK2
dependent in WT- but not DF508-CFTR expressing cell lines when exposed to Ps.
aeruginosa.
Conclusion: The data (Treharne et al 2007) are consistent with the idea that F508
is required for CK2 localisation to CFTR. A new collaboration funded by the
Italian CF Society with LA Pinna (Padua) is now shedding light on the mechanisms
involved leading to a new paradigm linking inﬂammation and ion transport in CF
due to malfunction of the CK2-DF508-CFTR interaction such that CK2 activity is
missing in the CF apical membrane.
Speculation: The ﬁnding that CFTR binds a known cancer inducing protein kinase
CK2 that targets another CFTR-bound cancer kinase (NDPK) whose function may
be abnormal in CF might explain the rising incidence of cancer in CF.
Supported by the Wellcome Trust, CF Trust and DFG.
R14 ROLE OF CFTR IN BILE SECRETION
M. Strazzabosco, C. Spirli, R. Fiorotto. Liver Center, Department of Internal
Medicine, Yale University School of Medicine, New Haven, CT, USA
In the liver, CFTR is selectively expressed by bile duct epithelium where it promotes
the transmembrane efﬂux of Cl− and bicarbonate. The biliary epithelium is the site
of rapid hormone-mediated regulation of the ﬂuidity and alkalinity of the primary
canalicular bile secreted by the hepatocytes. The net amount of ﬂuid and bicarbonate
secreted is determined by the integration of pro-secretory and anti-secretory signals.
Biliary epithelial cells (cholangiocytes) possess a polarized distribution of carriers
that mediate vectorial HCO−3 and ﬂuid secretion, under the endocrine control of
secretin/cAMP/PKA on the basolateral side and under the autocrine control of
extracellular ATP/P2Y-receptors/intracellular Ca2+ on the apical side. In cholangio-
cytes CFTR has multiple functions, including: (a) mediating cAMP-dependent Cl−
secretion in response to cAMP/PKA, (b) regulating the activity of the apical Na+/H+
and Cl−/HCO−3 exchangers, (c) modulating vesicle-mediated ﬂuid and electrolyte
transport, (d) facilitating the apical release of ATP. We have recently shown that
UDCA stimulates apical ATP secretion in a CFTR-dependent manner. Apical ATP,
thereby activating Ca2+-dependent Cl− channels, is then responsible for UDCA-
induced ductal choleresis. This is a novel mechanism with important implications
for the treatment of CF-related liver disease. In this regard it is important to consider
that CFTR-independent ﬂuid secretory pathways are also present in cholangiocytes.
We have recently shown that the sulphonylurea glibenclamide (GL) stimulates
vesicle-mediated secretion in bile ducts in a CFTR-independent manner. This effect
is maintained in CFTR-KO mice, in which GL is able to restores choleresis. Whether
these promising ﬁndings will be translated into CF treatment strategies is at present
unclear. The only liver-speciﬁc therapy for CF proposed to date is the use of ur-
sodeoxycholic acid (UDCA). Administration of UDCA slows the progression of the
disease in humans, however, the choleretic effect of UDCA on biliary cells depends
on its ability to stimulate a CFTR-dependent ATP secretion, suggesting that its
pharmacologic mechanisms in CF is different form stimulation of ductal choleresis.
R15 THE UK CF GENE THERAPY CONSORTIUM RESEARCH
PROGRAMME
U. Griesenbach. Imperial College London and the UK CF Gene Therapy
Consortium, United Kingdom
It has been suggested that modest increases in CFTR function (in the range of
5%) may be sufﬁcient to ameliorate lung disease severity. Although generally less
efﬁcient than viral vectors, we hypothesize that the transfection efﬁciency of the
best non-viral gene transfer agents may be sufﬁcient for clinical beneﬁt. In a large
pre-clinical study we have compared a number of non-viral gene transfer agents
and have chosen cationic lipid GL67 as our leading Wave 1 product. GL67 will
be complexed to a plasmid carrying the CFTR gene, which has been signiﬁcantly
improved compared to plasmids used in previous clinical trials. The plasmid has
been completely CpG-depleted to minimise inﬂammatory responses to the DNA and
importantly a promoter has been chosen that, at least in animal models, leads to
long-lasting (several weeks) gene expression. In our opinion, clinical beneﬁt of gene
therapy can only be assessed if gene expression is maintained over several months
and we are, therefore, preparing for a multi-dose clinical study designed to run for
12 months with monthly administration of GL67/DNA complexes or placebo (n = 50
subjects/group). Preparation for the multi-dose trial involves validation of novel
and established biomarkers as endpoint assays, identiﬁcation of criteria for patient
selection and importantly a single dose pilot trial to assess safety and duration
of gene expression in human. While the work-up for the clinical programme with
GL67 is moving forward, Consortium scientist are developing Wave 2 products in
an attempt to further improve gene transfer to the airway epithelium. Although most
viral vectors are not suitable for repeat dose clinical trials, lentiviral vectors are a
notable exception and may be suitable for CF gene therapy. Our pre-clinical data
using a F/HN-pseudotyped simian immunodeﬁciency virus-derived vector shows
that single administration leads to efﬁcient gene expression for up to 12 months
and, importantly, appears to be allow repeat administration. A summary of the pre-
clinical and clinical work currently carried out within the UK CF Gene Therapy
Consortium will be presented.
R16 NEW DRUGS TO CORRECT THE BASIC CF DEFECT
D.N. Sheppard. University of Bristol, Department of Physiology & Pharmacology,
School of Medical Science, Bristol, United Kingdom
Cystic ﬁbrosis (CF) is caused by mutations in the cystic ﬁbrosis transmembrane
conductance regulator (CFTR), a Cl− channel with complex regulation that plays an
essential role in ﬂuid and electrolyte transport across epithelia. CFTR is assembled
from ﬁve domains: two membrane-spanning domains that form an anion-selective
pore, two nucleotide-binding domains (NBDs) that control channel gating and a
unique regulatory domain phosphorylation of which is a prerequisite for channel
activity.
By far the most common CF mutation is F508del, the deletion of a phenylalanine
residue at position 508 of the CFTR sequence. This mutation accounts for about
70% of CF mutations worldwide and is associated with a severe disease phenotype.
The F508del mutation disrupts the expression and function of CFTR in at least
three different ways. First and foremost, deletion of F508 causes misfolding of
CFTR protein, leading to the retention of the vast majority of the mutant protein
in the ER and its degradation by the proteasome. Second, decreased stability of
F508del-CFTR protein at the cell surface. Any F508del-CFTR that reaches the
apical membrane resides there for only a fraction of the time of wild-type CFTR.
Third, altered channel gating. F508del-CFTR Cl− channels exhibit a profound defect
in channel gating characterised by infrequent bursts of channel openings separated
by long closures of prolonged duration compared to those of wild-type CFTR.
Restoration of channel function to F508del-CFTR requires a drug to deliver the
mutant protein to the apical membrane (termed a CFTR corrector) and a drug to
rescue defective channel gating (termed a CFTR potentiator). A number of small
molecules have been identiﬁed (e.g. VRT-325 and Corr-4a) that rescue the cell
surface expression of F508del-CFTR [1,2]. Of note, VRT-325 and Corr-4a also
enhance the stability of F508del-CFTR at the apical membrane of CF epithelia [3].
A large number of small molecules have been identiﬁed (e.g. VRT-532), which act
as CFTR potentiators, rescuing the gating defect of F508del-CFTR [1]. Many of
these agents interact directly with the NBDs of CFTR to promote, and stabilise,
the formation of an NBD dimer, which controls channel gating. This presentation
will highlight how knowledge of the molecular pharmacology of CFTR is leading
to the development of new treatments for CF.
Reference(s)
[1] Van Goor F. et al. Am J Physiol (2006) 290, L1117–1130.
[2] Pedemonte N. et al. J Clin Invest (2005) 115, 2564–2571.
[3] Varga K. et al. Pediatr Pulmonol Suppl (2007) 30, 288.
R17 THE EUROPEAN CYSTIC FIBROSIS REGISTRY
A. Mehta1, G. Mehta1, H. Olesen2, M. Macek3. 1Maternal and Child Health
Sciences, University of Dundee, United Kingdom; 2Pediatric Dept. Aarhus
University Hospital Skejby, Denmark; 3Institute of Biology and Medical Genetics,
Charles University Prague, Czech Republic
The European CF Registry project aims to unite cystic ﬁbrosis data collection
across continents. The project has received support from the European Commission
(Framework 6, EuroCareCF, work package 2) which runs from 2006−9. The core
objective is to create a common data structure between the United States and Europe
for use by European CF Centres and after the project is complete, it is planned to
use this structure to analyse the comparative demographics of CF. Our partners
include the Cystic Fibrosis Foundation of the United States who have supplied
their software (Port CF) for all participating European CF centres together with the
European CF Society (ECFS) who have supplied their data handling expertise and
logistic support. EuroCareCF work package 2 aims to provide solutions to the key
ethical, legal, practical, data protection and social hurdles that must be overcome
as described on our web site (www.eurocarecf.eu).
Methodology is described on the web site. Crucially, the design is such that a
CF centre based approach to collect the data maintains anonymity whilst enabling
countries to compile their own aggregate country speciﬁc reports with the express
consent of each CF Centre.
